Donepezil in the treatment of mild to moderate Alzheimer's disease: report of a Belgian multicenter study.
In this report the results of a Belgian multicenter 24-week open-label study with donepezil in the treatment of mild to moderate Alzheimer's disease are described. Efficacy and safety were evaluated in a sample of 200 patients recruited in 25 Belgian centers. No significant changes could be found in cognition and behaviour over this 6-month period. Changes in daily functioning were small. Safety data were comparable to those reported in international trials. These results suggest that the findings of more robust double-blind, placebo-controlled studies can be confirmed in real life situations.
Santens
P
P
Department of Neurology, Ghent University Hospital. Patrick.Santens@UGent.be
Ventura
M
M
D000203:Activities of Daily Living; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D001530:Belgium; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D003071:Cognition / Q000187:drug effects*; D000077265:Donepezil; D005260:Female; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D009483:Neuropsychological Tests; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology*
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil